Citadel Advisors
NKTR icon

Citadel Advisors’s Nektar Therapeutics NKTR Stock Holding History

Citadel Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.16M Buy
113,400
+21,800
+24% +$1.24M ﹤0.01% 3553
2025
Q4 		$3.87M Sell
91,600
-42,676
-32% -$2.39M ﹤0.01% 4717
2025
Q3 		$7.64M Sell
134,276
-75,992
-36% -$2.52M ﹤0.01% 3647
2025
Q2 		$5.43M Buy
210,268
+207,081
+6,498% +$2.33M ﹤0.01% 3958
2025
Q1 		$32.5K Sell
3,187
-326
-9% -$4.26K ﹤0.01% 12744
2024
Q4 		$49K Buy
3,513
+2,660
+312% +$46.9K ﹤0.01% 12412
2024
Q3 		$16.6K Buy
853
+726
+572% +$13.8K ﹤0.01% 12920
2024
Q2 		$2.36K Sell
127
-1,093
-90% -$23K ﹤0.01% 13695
2024
Q1 		$17.1K Buy
1,220
+547
+81% +$5.73K ﹤0.01% 13115
2023
Q4 		$5.71K Buy
673
+133
+25% +$1.01K ﹤0.01% 13408
2023
Q3 		$4.82K Sell
540
-1,200
-69% -$11.6K ﹤0.01% 13449
2023
Q2 		$15K Sell
1,740
-4,347
-71% -$46.4K ﹤0.01% 12969
2023
Q1 		$64.2K Buy
6,087
+5,374
+754% +$163K ﹤0.01% 11840
2022
Q4 		$24.2K Sell
713
-2,347
-77% -$114K ﹤0.01% 12977
2022
Q3 		$147K Sell
3,060
-2,213
-42% -$132K ﹤0.01% 10724
2022
Q2 		$301K Sell
5,273
-12,854
-71% -$811K ﹤0.01% 9795
2022
Q1 		$1.47M Buy
18,127
+14,414
+388% +$2.13M ﹤0.01% 6779
2021
Q4 		$753K Sell
3,713
-4,700
-56% -$1.02M ﹤0.01% 8642
2021
Q3 		$2.27M Buy
8,413
+3,546
+73% +$853K ﹤0.01% 6036
2021
Q2 		$1.25M Sell
4,867
-673
-12% -$186K ﹤0.01% 7748
2021
Q1 		$1.66M Sell
5,540
-10,967
-66% -$3.41M ﹤0.01% 6851
2020
Q4 		$4.21M Buy
16,507
+1,360
+9% +$351K ﹤0.01% 3965
2020
Q3 		$3.77M Sell
15,147
-3,733
-20% -$1.17M ﹤0.01% 3581
2020
Q2 		$6.56M Sell
18,880
-1,253
-6% -$391K ﹤0.01% 2705
2020
Q1 		$5.39M Buy
20,133
+6,700
+50% +$2.07M ﹤0.01% 2606
2019
Q4 		$4.35M Buy
13,433
+2,866
+27% +$831K ﹤0.01% 3251
2019
Q3 		$2.89M Buy
10,567
+2,567
+32% +$941K ﹤0.01% 3901
2019
Q2 		$4.27M Sell
8,000
-220
-3% -$110K ﹤0.01% 3332
2019
Q1 		$4.14M Sell
8,220
-3,527
-30% -$2.09M ﹤0.01% 3262
2018
Q4 		$5.79M Sell
11,747
-933
-7% -$563K ﹤0.01% 2579
2018
Q3 		$11.6M Sell
12,680
-1,940
-13% -$1.66M 0.01% 1940
2018
Q2 		$10.7M Buy
14,620
+9,593
+191% +$11.1M 0.01% 1865
2018
Q1 		$8.01M Buy
5,027
+980
+24% +$1.26M ﹤0.01% 1940
2017
Q4 		$3.63M Buy
4,047
+654
+19% +$387K ﹤0.01% 2863
2017
Q3 		$1.22M Buy
3,393
+1,793
+112% +$561K ﹤0.01% 4031
2017
Q2 		$469K Sell
1,600
-87
-5% -$25.1K ﹤0.01% 5210
2017
Q1 		$594K Buy
1,687
+167
+11% +$37.5K ﹤0.01% 4750
2016
Q4 		$280K Sell
1,520
-153
-9% -$31.1K ﹤0.01% 5778
2016
Q3 		$431K Buy
1,673
+473
+39% +$122K ﹤0.01% 5081
2016
Q2 		$256K Sell
1,200
-360
-23% -$80.5K ﹤0.01% 5456
2016
Q1 		$322K Buy
1,560
+607
+64% +$117K ﹤0.01% 5010
2015
Q4 		$241K Buy
953
+213
+29% +$43.8K ﹤0.01% 5538
2015
Q3 		$122K Sell
740
-300
-29% -$53.1K ﹤0.01% 6759
2015
Q2 		$195K Sell
1,040
-673
-39% -$116K ﹤0.01% 6360
2015
Q1 		$283K Buy
1,713
+880
+106% +$181K ﹤0.01% 5737
2014
Q4 		$194K Sell
833
-434
-34% -$92.8K ﹤0.01% 6010
2014
Q3 		$229K Buy
1,267
+520
+70% +$99.5K ﹤0.01% 5589
2014
Q2 		$144K Sell
747
-220
-23% -$38.9K ﹤0.01% 5901
2014
Q1 		$176K Sell
967
-146
-13% -$28.9K ﹤0.01% 5652
2013
Q4 		$190K Sell
1,113
-1,547
-58% -$250K ﹤0.01% 5075
2013
Q3 		$417K Buy
2,660
+1,933
+266% +$357K ﹤0.01% 4003
2013
Q2 		$126K Buy
+727
New +$112K ﹤0.01% 5051

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors's NKTR Position: Q1 2026 in Review

Citadel Advisors increased its Nektar Therapeutics (NKTR) stake by 66% in Q1 2026, buying an estimated $11.6M and bringing the position to 513,531 shares worth $36.9M. The position accounts for 0.01% of the portfolio, ranked #1649.

Citadel Advisors first reported a position in NKTR in Q2 2013 and has held it in 45 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Citadel Advisors held 513,531 shares of Nektar Therapeutics worth $36.9M as of Q1 2026.
  • Citadel Advisors bought 203,754 Nektar Therapeutics shares in Q1 2026, an estimated $11.6M.
  • Nektar Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1649 holding.
  • Citadel Advisors first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.